Abstract: Programmed cell death (apoptosis) plays a vital role in the regulation of cellular homeostasis. Because of apoptosis fundamental importance, this process is highly regulated. One important set of factors involved in apoptosis regulation is the Bcl-2 family proteins. Bcl-2 family members form a complex regulatory network that controls cell survival and death in response to different physiological and pathological signals. This family includes both pro-and anti-apoptotic members, and Bax protein (Mol wt 21 kDa) is a major pro-apoptotic factor with multifunctional activity. This review summarizes new data about the main representative of Bcl-2 family -Bax, its structure and mechanism(s) by which this protein modulates apoptosis.
INTRODUCTION
Apoptosis is a precisely controlled mode of eliminating injured, mutated or unwanted cells from the body or an organ of multicellular organism that, in contrast to necrosis, does not trigger the inflammation (HENGARTNER 2000; WYLLIE 2010) . It is widely accepted that apoptosis may go through two major pathways (extrinsic and intrinsic), one of which involves mitochondria with proteins localized inside the intermembrane compartment of these organelles (KILIAŃSKA 2002) . The mitochondrial (intrinsic) pathway of apoptosis is activated in response to several Mcl-1 (Myeloid cell leukemia-1), Bcl-B (Bcl-2 family protein resembling Boo) and A1/Bfl-1 (KE et al. 2001; BORNER 2003; CORY et al. 2003; DROIN, GREEN 2004; REED 2008; SCHRÖDER 2008) . These subfamily members typically possess 4 BH domains in their structure and they are usually anchored to intracellular membranes of the cell.
-Bax-like death factors -multi-domain pro-apoptotic proteins e.g. Bax (Bcl-2 associated x protein), Bak (Bcl-2 antagonist/killer 1), Bok/Mtd (Bcl-2-related ovarian killer/Spanish: Matador -the killer), Bcl-X S . They have three (or 4 in case of Bok/Mtd) BH domains and play a role as effector molecules capable of directly inducing mitochondrial permeabilization and apoptosis (BORNER 2003) .
-BH3-only death factors -single-domain pro-apoptotic proteins e.g. Bad (Bcl-2 antagonist of cell death is equivalent to Bcl-2 associated death promoter), Bid (BH3-interacting domain death agonist), Bik (Bcl-2 interacting killer), Bim (Bcl-2 interacting mediator of cell death), Bmf (Bcl-2 modifying factor), BNIP3 (Bcl-2 and adenovirus E1B 19-kDa protein interacting protein 3), Bnip3L (Bnip3-like), Hrk (Harakiri), Noxa/APR, Puma (p53-upregulated modulator of apoptosis) and Spike (Small protein with inherent killing effect). The members of this subfamily contain exclusively one domain -BH3; some of BH3-only proteins contain transmembrane domain, TM. They interact with Bax-like as well as Bcl-2-like proteins determining the fate of a cell (GUO et al. 2001; MOLDOVEANU et al. 2006; SKOMMER et al. 2007; HOSSINI, EBERLE 2008; REED 2008) .
Recently, several other pro-apoptotic proteins have been discovered, however their classification turned out to be very difficult due to the presence of only two BH domains in their structure. For example, Bfk (Bcl-2 family kin) and Bcl-G proteins contain BH2 and BH3 while Bcl-X S (Bcl-2 related gene, short isoform) and Bcl-X AK (Bcl-2 related gene, alternative killer) are equipped with BH3 Main pro-apoptotic member of Bcl-2 family proteins -Bax 8 and BH4 or BH2 and BH4 domains, respectively; the latter is usually connected with anti-apoptotic potential of proteins (BORNER 2003; KARST, LI 2007; HOSSINI, EBERLE 2008) . Similarly, Bcl-rambo shares the structural homology with antiapoptotic factors of Bcl-2 family although its overexpression induces apoptosis (KATAOKA et al. 2001; HOSSINI, EBERLE 2008) . Boo/Diva (Death inducer binding to vBcl-2 and Apaf-1) protein that comprises 4 BH domains may in turn act as proapoptotic or pro-survival molecule depending on the cellular context (LEE et al. 2001) . BH3-only -B) is divided into 3 functional subfamilies (1, 2, and 3) based on their composition of BH (1-4) domains. For more details see text. α1-9 -α-helices; BHBcl-2 homology domain; TM -transmembrane domain. The BH3 domain in the pro-apoptotic proteins is a ligand for the hydrophobic pocket formed by the BH1-BH3 domains of the anti-apoptotic members of Bcl-2 family.
The classification of Bcl-2 family proteins based on their role in apoptosis seems to be rather conventional since the phenotype of many pro-or anti-apoptotic proteins can be changed into the opposite one under some special conditions (LIN et al. 2004; HANSON et al. 2008) . For example, Bcl-X L protein, known as antiapoptotic factor, may interact with mitochondria and induce OMM permeabilization after the binding phosphorylated K-Ras (phosphorylation on Ser
181
). Likewise, interaction of Bcl-2 protein with orphan receptor -Nur 77 (Nuclear receptor 77) converts the anti-apoptotic potential of Bcl-2 to pro-apoptotic (KOLLURI et al. 2008) .
It was demonstrated that Nur 77 also affected other generally anti-apoptotic proteins, such as Bcl-B, A1/Bfl-1, leading to reversion of their phenotype (LUCIANO et al. 2007 ).
Structure of Bcl-2 family proteins
Examination of the solution structure of Bcl-2 family proteins revealed some structural resemblances between pro-and anti-apoptotic molecules. These proteins adopt donut-shaped structure with two central, hydrophobic α-helices surrounded with 6-7 amphipathic α-helical regions. Additionally, they contain a long (60 aa), unstructured loop between the first and the second helical region of proteins (PETROS et al. 2004; SKOMMER et al. 2007; BORNER 2003) .
BH1, BH2, and BH3 domains play an important role in the interactions of anti-apoptotic proteins with their pro-apoptotic opponents (PETROS et al. 2004; HOSSINI, EBERLE 2008) ]. In pro-survival as well as in inactive pro-apoptotic proteins above domains form together a hydrophobic pocket which binds BH3 motif of proapoptotic molecule by electric and hydrophobic interactions (BORNER 2003; PETROS et al. 2004; HOSSINI, EBERLE 2008 and BH3 domain of pro-death factor. It was indicated that the substitution of Gly145Ala/Glu and Trp188Ala prevented the heterodimerization of Bcl-2 family proteins, suggesting that these residues take part in the binding of hydrophobic clef to BH3 domain (GURUDUTTA et al. 2005) .
The in vitro tests revealed that both Bax and Bcl-2 proteins were able to form channels permeable for chloride or potassium ions, respectively in the membranes (CHRISTENSON et al. 2008) . It has been shown that negatively charged phospholipid -cardiolipin supports the pore-forming activity of Bax whereas cholesterol-rich bilayers inhibit
Bax integration into the membranes (CHRISTENSON et al. 2008 ).
BH3 domain is composed of 9-16 amino acid residues highly conserved among all Bcl-2 family proteins. It fulfils the role of ligand binding region which is necessary for both hetero-and homo-dimerization and apoptosis triggering (FREY et al. 2008) . The BH3 domain of anti-apoptotic proteins is an integral part of hydrophobic cleft built with BH1, BH2 and BH3 in contrast to the BH3 domains of pro-apoptotic factors of this family which are hidden inside the molecules of inactive proteins or are exposed to the outside of the molecules when they are active (BORNER 2003; PETROS et al. 2004) . Unbound BH3 domain of free pro-apoptotic proteins indicates unorganized structure while after their dimerization with prosurvival partners it forms amphiphatic helix penetrating the hydrophobic pocket (BORNER 2003) . It is worth mentioning that the substitution of Asp 160 in BH3 domain of Bad with Arg that facilitates the adoption of α-helical structure widely increased the affinity of BH3 peptide to Bcl-X L protein (PETROS et al. 2004 ).
In addition, the amino acid sequence of Bcl-2 family proteins plays an important role for this interaction. It has been reported that conserved residues -Leu and Asp occupy the position 1 and 6 of BH3 domain in all Bcl-2 family members, whereas Ala or any hydrophobic amino acid (usually Ile) is situated at position 4 of BH3 domain in anti-or pro-apoptotic proteins, respectively.
BH4 domain is localized in amino terminal region of anti-apoptotic Bcl-2 family members as well as some pro-apoptotic proteins (Bcl-x s , Bcl-rambo, Bok/Mtd, Boo/Diva) (HOSSINI, EBERLE 2008) . For a long time, it was thought that BH4 domain was responsible for apoptosis inhibiting activity of pro-survival molecules (HOSSINI, EBERLE 2008) . However, some anti-apoptotic proteins, e.g.
Mcl-1, do not possess the above conserved region, but they all include a helical region − α1. In most of anti-apoptotic proteins this motif is enclosed in the BH4 domain. Currently, it seems that just this helical structure controls pro-survival function of Bcl-2 inhibitors regardless of its amino acid sequence. Similar α-helical region was found in Bax molecule in which it negatively regulates pro-apoptotic function of this protein (CARTRON et al. 2004 ).
Some anti-apoptotic Bcl-2 family members contain a 60-aa regulatory loop between α-1 and α-2 helices that seems to work as a region of autoinhibition (Lin 2004 , PETROS et al. 2004 . Chemical modifications (such as phosphorylation) within a given region result in abolishing the pro-survival potential of anti-apoptotic proteins and conversion of their phenotype.
Most of Bcl-2 family representatives contain a C-terminal 15-20-aa hydrophobic sequence -transmembrane (TM) domain -neighboring positivelycharged amino acid residues of Lys or Arg, that enables them to attach to the membranes of mitochondria, endoplasmic reticulum or cell nuclei (PETROS et al. 2004; SCHINZEL et al. 2004a) . Some of the proteins anchor to membranes immediately after their synthesis while others possess a transmembrane domain hidden inside their molecule and require to pass some conformational changes to expose TM on the surface (BORNER 2003; SCHINZEL et al. 2004a) .
BAX PROTEIN -A KEY EFFECTOR IN MITOCHONDRIAL PATHWAY OF APOPTOSIS
Human Bax gene is located on long arm of chromosome 19 within the region q13.3-q13.4 (APTE et al. 1995) . This gene is about 4500 bp long and contains six exons. Alternative splicing of its primary transcript produces several isoforms of Bax (α, β, γ, δ, ω, σ and Ψ) (CARTRON et al. 2002; DROIN, GREEN 2004) . In ischemic rat brain a novel splice variant of Bax, Bax κ, was identified (JIN et al. 2001) . Main variant, firstly isolated -Baxα is encoded by all exons and has a molecular weight However, this feature is thought to be reversible and independent of pro-survival Bcl-2 proteins (BORNER 2003; SHARPE et al. 2004) . It would seem that the 6A7 epitope exposition on the surface of Bax appears at very early stage of its conformational changes and it precedes protein oligomerization. Therefore, this immunoreactivity elevation can not be strictly identified with Bax activation and apoptosis induction (SHARPE et al. 2004 ). In addition, it is believed that Bax translocation and oligomerization are not enough to induce permeabilization of OMM, although they both are required (SKOMMER et al. 2007) .
Bax protein shares a strong similarity of its tertiary structure with antiapoptotic members of Bcl-2 family, such as Bcl-2 and Bcl-X L (SUZUKI et al. 2000; BORNER 2003; PETROS et al. 2004) . Above polypeptide contains 9 α-helices. The seven of them surround two centrally-localized hydrophobic α-helical structures.
The helix α5 is positioned the most internally in the molecule. Between helices α-1 and α-2 a long flexible loop region can be observed. BH1, BH2 and BH3 domains of the described protein, embraced with α-2, α-3 and α-4 helices, lay in the same orientation as the domains of Bcl-X L . In living cells they form hydrophobic cleft in analogous manner as anti-apoptotic proteins. It prevents from Bax dimerization under normal conditions (DROIN, GREEN 2004 in the interaction between C-terminus of Bax and α4 region of its hydrophobic pocket (SUZUKI et al. 2000) . It is also possible that C-terminus of Bax protein takes part in pocket stabilization and plays a role in the regulation of its translocation and oligomerization (SUZUKI et al. 2000; CARTRON et al. 2004) . If the C-terminus of Bax is folded the pocket remains in a stable conformation. While the region is removed out of the hydrophobic cleft, the pocket collapses and the protein structure changes leading to protein dimerization and to its interaction with mitochondrial membrane.
It is suggested that a removal of α-9 helical region (TM) is initiated by and α9 and uncovering of one of them after conformational changes of Bax, directs the molecule to mitochondrial membrane. It has been revealed that only combined mutations in both of these regions preclude its mitochondrial translocation in HeLa cell line.
MECHANISMS OF BAX-INDUCED MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION
Bcl-2 family proteins regulate apoptosis via their influence on mitochondrial membrane permeability and efflux of pro-apoptotic factors from intermembrane Importantly, Bax may cooperate with proteolytically truncated BH3-only member Bid (tBid) and Ca 2+ in permeabilizing the outer mitochondrial membrane and releasing mitochondrial apoptogenic factors (LUO et al. 1998; WEI et al. 2000; DESAGHER et al. 1999; BEDNAREK, KILIAŃSKA 2005; BRUSTOVETSKY et al. 2010) .
Recent data have indicated that Bax and tBid together may induce the formation of a large lipid pore in mitochondrial membrane (TERRONES et al. 2004) . It has been revealed that both of these proteins destabilize the structure of lipid bilayer and provoke pore formation. tBid protein facilitates lipid pore forming through its CBD domain (cardiolipin-binding domain) that directs pro-apoptotic proteins to cardiolipin-rich membranes (TERRONES et al. 2004 ).
Both, Bcl-2 and Bax proteins seem to be also involved in the regulation of 
REGULATORS OF BAX ACTIVITY

Activators of Bax protein
The main regulators of pro-apoptotic activity of Bax-like proteins are BH3-only members of Bcl-2 family. They may be divided into two subgroups depending on the way how they reveal pro-apoptotic potential of the so-called effectors (CHIPUK et al. 2006; LEBER et al. 2007; SKOMMER et al. 2007) : In addition, Bax can also interact with P53-dependent protein -ASC (Apoptosis associated speck-like protein containing a caspase recruitment domain) which moves to mitochondria after apoptosis induction and, in this way, facilitates Bax relocation (LEBER et al. 2007) . Similarly, it has been indicated that histone H1.2 trafficking is a part of events leading to Bcl-2 family pro-apoptotic proteins activation, mitochondrial membrane permeabilization and apoptosis induction upon cell death stimulation (YAN, SHI 2003) . It is unclear, however, how exactly H1.2 histone acts to provoke Bax/Bak oligomerization after its release to the cytosol.
It is worth mentioning that under special environmental circumstances, Bax and Bak molecules, can be activated in vitro without contribution of any additional proteins e.g. in response to nonionic detergents, pH increase or growth of temperature (BORNER 2003) . Nevertheless, it is not known if this kind of Bax activation occurs under physiological conditions.
Inhibitors of Bax protein
Among Bax regulators, with the exception of Bcl-2-like proteins that neutralize pro-apoptotic function of Bax, Ku70 protein -a component of DNA-PK (DNA-dependent protein kinase), 14-3-3 protein, and some Hsp proteins (Heat shock proteins) (αA and αB-crystalins, Hsp70/dj1 and Hsp70/dj2 complexes) are found (LUCKEN-ARDJOMANDE, MARTINOU 2005; GOTOH et al. 2004; SHARPE et al. 2004; SCHINZEL et al. 2004a) . Anti-apoptotic activities of the above factors are probably associated with a sequestering of inactive Bax molecule in the cytosol. It has been revealed that the proteins abrogate apoptosis induced by several agents e.g., UV irradiation or staurosporine treatment, while their removal from the cells enhances cell susceptibility towards apoptosis.
Additionally, ASO (antisense oligonucleotides) strategy showed antiapoptotic potential of ARC protein (Activity-regulated cytoskeleton-associated protein), a factor, that is highly expressed in cardiac and skeletal muscle cells (LUCKEN-ARDJOMANDE, MARTINOU 2005) . It was shown that the silencing of ARC expression contributed to conformational changes in the pro-apoptotic molecule Bax and mediated apoptosis. Bax activation and translocation can be brought to a halt by a new endogenous peptide -humanin, too (ZHAI et al. 2005) . It was indicated that this 24-aa peptide is able to bind both with Bax and its direct activator -Bid (and tBid) and to inhibit tBid-induced Bax oligomerization.
It has been also suggested that Bax mediated apoptosis can be abolished by hexokinase-mitochondria interaction in a process regulated by Akt/PKB kinase activity (MAJEWSKI et al. 2004 ).
In 1998, XU and REED reported about the new anti-apoptotic protein, BI-1 (Bax inhibitor 1), discovered by functional screening in yeast. Above inhibitor is
Main pro-apoptotic member of Bcl-2 family proteins -Bax 20 highly conserved in animals and plants (XU, REED 1998; HÜCKELHOVEN 2004) . It has been well documented that BI-1 protein abrogates apoptosis followed by a large number of apoptotic stimuli, e.g. Bax overexpression, growth factor and cytokine deprivation, drug treatment (etoposide, staurosporine), bacterial pathogens (e.g.
Chlamydia psittacci) in various cell lines (HÜCKELHOVEN 2004) . This protein neutralizes pro-apoptotic function of Bax. However, the mechanism of BI-1 action does not seem to be related to its physical interaction with Bax molecule. These two proteins do not appear to associate with themselves.
The main negative regulators of pro-apoptotic function of Bax are Bcl-2 family proteins. Bax can heterodimerize with Bcl-2, Bcl-X L , Bcl-w and, perhaps, with Mcl-1 proteins and these interactions prevent apoptosis in live cells (DROIN, GREEN 2004; EWINGS et al. 2007) . After apoptosis induction, the release of Bax from the complexes with proteins that counteract its function takes place due to the fact that BH3-only proteins indicate approximately 100 times stronger affinity for anti-apoptotic Bcl-2-like members than their affinity for Bax (BORNER 2003) . Free
Bax molecules multimerize and/or interact with the components which already exist in the mitochondrial membranes forming a large channel permeable for cytochrome c and other pro-death factors. Thus, the cell fate depends essentially on the equilibrium between pro-survival and pro-apoptotic proteins. Indeed, it is well known that disruption of the balance between Bcl-2 family partners in the cells entails serious consequences manifested in the disorder of life-or-death decision and on the one hand, cell accumulation, or on the other hand, excessive cell elimination.
Defective apoptosis causes a large number of diseases, including cancers, autoimmune syndromes, neurodegenerative disorders, diabetes, immunodeficiency syndromes, infertility (KILIAŃSKA 2002; PEREZ et al. 1997; BORNER 2003; HAYASHI, FAUSTMAN 2003; MOLDOVEANU et al. 2006; FREY et al. 2008 ).
BCL-2 FAMILY PROTEINS -NEW TARGET FOR THE THERAPY OF DISORDERS WITH DEFECTIVE APOPTOSIS
In viable cells pro-apoptotic proteins co-exist in dynamic balance with antiapoptotic counterparts from Bcl-2 family (DAY et al. 2008 (CASTLE et al. 1993; CORNBLAU et al. 1999; DROIN, GREEN 2004) . Correspondingly, Baxα gene is mutated in many cancers (e.g. derived from colorectum, stomach, endometrium cells) and its expression level influences on the effectiveness of apoptosis induction (BARGOU et al. 1995 , WAGENER et al. 1996 RAMPINO et al. 1997; OUYANG et al. 1998; REED 1999; FERREIRA et al. 2002) .
Therefore, Bax/Bcl-2 ratio may reflect susceptibility of neoplastic cells to spontaneous as well as drug-induced apoptosis. For instance, the cellular level of Bax and Bcl-2 proteins in prostate cancer cells is a predictive factor forecasting the result of the therapy based on androgen deprivation and radiation (KHOR et al. 2007 ). It has been also shown that Bax/Bcl-2 rate in chronic lymphocytic leukemia (CLL) inversely correlates with resistance of leukemic cells to cytotoxic drugchlorambucil in vitro as well as with clinical responsiveness (PEPPER et al. 1997) .
Above parameter mirrors the potential of the examined cells to apoptosis induction and its analysis may serve in vitro as potential tool for evaluating whether neoplastic cells are drug resistant or not (KOBYLINSKA et al. 2006 ).
Owing to the key role of Bcl-2 family proteins in apoptosis regulation they are an attractive target for modern anti-cancer therapy. There are many therapeutical approaches leading to modification of cellular balance between pro-and antiapoptotic Bcl-2 family molecules. Most of them are targeted to pro-survival proteins and are based on antisense oligonucleotides (JANSEN et al. 1998; KONOPLEVA et al. 2000; FERREIRA et al. 2002) . However, the number of trials aiming at inducing Bax Main pro-apoptotic member of Bcl-2 family proteins -Bax 22 gene in tumor cells is growing all the time (WAGENER et al. 1996; LI et al. 2001; PIROCANAC et al. 2002; FALKE et al. 2003) . As the introduction of a vector expressing Bax gene into cells involves a lot of difficulties associated with putative toxic effect of its protein product on normal cells, it is a great challenge for scientists to cause a cancer cell-directed expression of this gene (SEO et al. 2009 ).
A new engineered artificial transcription factor, 5ZFAV, seems to be a solution to this problem (FALKE et al. 2003) . It has been revealed that 5ZFAV, containing zinc fingers from mouse Zif268 and transactivation domain from herpes simplex virus protein, VP16, selectively induces the expression of endogenous Bax and efficiently turns apoptosis on in P53-deficient sarcoma osteogenic Saos-2 cells.
Interestingly, the impact of the novel molecule on P53 positive osteosarcoma cell line -U-2 OS appears to be much less potent giving the chance for selective proapoptotic activity against P53-mutated tumor cells.
The Tet-On inducible system, containing reverse tetracycline transactivator (rtTA) and inducing transcription after the binding with tetracycline and its derivatives, seems to be very helpful in controlling Bax gene expression (WAGENER et al. 1996 , SEO et al. 2009 ). It has been reported that the stable transfectants obtained from DLD-1 colon cancer cells transfected with above system (pTET-On and p-TRE Bax plasmids) and selected in the medium with geneticin, occur to be more sensitive to various drug-induced apoptosis than the cells without introduced Bax gene (KOBAYASHI et al. 2000) .
On the other hand, it has been discovered that bax inactivation in oocytes of mice undergoing treatment with doxorubicine reduced their sensitivity to apoptosis and increased their viability (PEREZ et al. 1997 ). Since it is well known that development of infertility in anticancer drugs-treated women is one of the most common side effect of chemotherapy, the inhibition of Bax gene in germinal cells during the chemotherapy of cancer could be interesting strategy of infertility preservation (PEREZ et al. 1997 ).
In conclusion, it seems that overexpression of Bax alone in cancer cells does not induce apoptosis but enhances its induction following anticancer treatment. A combination of conventional chemotherapy with gene therapy may be a new, very potent strategy in cancer treatment. It is conceivable that the better understanding of apoptosis regulation may help to overcome apoptosis deficiency (typical in many cancers) and therapy resistance.
